MedMira Inc. (MIR.V)
CAD 0.1
(5.56%)
CAD 0.1
(5.56%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.94 Million CAD | -33.79% |
| 2022 | -1.45 Million CAD | -688.8% |
| 2021 | -184.23 Thousand CAD | 85.83% |
| 2020 | -1.3 Million CAD | -0.32% |
| 2019 | -1.29 Million CAD | 29.57% |
| 2018 | -1.84 Million CAD | 13.73% |
| 2017 | -2.13 Million CAD | 52.37% |
| 2016 | -4.47 Million CAD | -81.22% |
| 2015 | -2.47 Million CAD | 30.74% |
| 2014 | -3.56 Million CAD | -64.8% |
| 2013 | -2.16 Million CAD | -0.23% |
| 2012 | -2.16 Million CAD | -16.34% |
| 2011 | -1.85 Million CAD | 20.55% |
| 2010 | -2.33 Million CAD | 7.49% |
| 2009 | -2.52 Million CAD | 22.22% |
| 2008 | -3.24 Million CAD | 9.01% |
| 2007 | -3.57 Million CAD | 34.83% |
| 2006 | -5.47 Million CAD | -23.18% |
| 2005 | -4.44 Million CAD | -27.27% |
| 2004 | -3.49 Million CAD | 18.93% |
| 2003 | -4.31 Million CAD | 15.69% |
| 2002 | -5.11 Million CAD | 23.7% |
| 2001 | -6.7 Million CAD | -102.62% |
| 2000 | -3.3 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -536.32 Thousand CAD | 10.33% |
| 2024 Q1 | -598.09 Thousand CAD | -34.64% |
| 2024 Q3 | -656.81 Thousand CAD | -12.45% |
| 2023 FY | -1.94 Million CAD | -33.79% |
| 2023 Q3 | -632.41 Thousand CAD | -71.01% |
| 2023 Q4 | -444.2 Thousand CAD | 29.76% |
| 2023 Q2 | -369.8 Thousand CAD | 25.72% |
| 2023 Q1 | -497.88 Thousand CAD | -21.83% |
| 2022 Q2 | -359.61 Thousand CAD | 7.56% |
| 2022 Q1 | -389.03 Thousand CAD | 36.4% |
| 2022 FY | -1.45 Million CAD | -688.8% |
| 2022 Q4 | -408.68 Thousand CAD | -38.12% |
| 2022 Q3 | -295.89 Thousand CAD | 17.72% |
| 2021 Q3 | -197.46 Thousand CAD | 23.58% |
| 2021 Q1 | 883.35 Thousand CAD | 1810.33% |
| 2021 Q2 | -258.39 Thousand CAD | -129.25% |
| 2021 Q4 | -611.72 Thousand CAD | -209.79% |
| 2021 FY | -184.23 Thousand CAD | 85.83% |
| 2020 Q2 | -432.54 Thousand CAD | -52.68% |
| 2020 Q4 | -51.64 Thousand CAD | 90.3% |
| 2020 Q1 | -283.3 Thousand CAD | 7.62% |
| 2020 Q3 | -532.65 Thousand CAD | -23.14% |
| 2020 FY | -1.3 Million CAD | -0.32% |
| 2019 Q1 | -306.72 Thousand CAD | 4.6% |
| 2019 FY | -1.29 Million CAD | 29.57% |
| 2019 Q2 | -373.3 Thousand CAD | -21.7% |
| 2019 Q3 | -309.31 Thousand CAD | 17.14% |
| 2019 Q4 | -306.68 Thousand CAD | 0.85% |
| 2018 FY | -1.84 Million CAD | 13.73% |
| 2018 Q1 | -467.25 Thousand CAD | -25.75% |
| 2018 Q3 | -511.93 Thousand CAD | 5.13% |
| 2018 Q2 | -539.59 Thousand CAD | -15.48% |
| 2018 Q4 | -321.51 Thousand CAD | 37.2% |
| 2017 Q4 | -371.58 Thousand CAD | 40.57% |
| 2017 Q2 | -428.87 Thousand CAD | 39.38% |
| 2017 FY | -2.13 Million CAD | 52.37% |
| 2017 Q1 | -707.47 Thousand CAD | 63.01% |
| 2017 Q3 | -625.22 Thousand CAD | -45.78% |
| 2016 Q1 | -709.93 Thousand CAD | -531.43% |
| 2016 Q4 | -1.91 Million CAD | -83.73% |
| 2016 Q3 | -1.04 Million CAD | -27.66% |
| 2016 FY | -4.47 Million CAD | -81.22% |
| 2016 Q2 | -815.43 Thousand CAD | -14.86% |
| 2015 Q1 | -745.07 Thousand CAD | 9.5% |
| 2015 FY | -2.47 Million CAD | 30.74% |
| 2015 Q4 | -112.43 Thousand CAD | 83.29% |
| 2015 Q3 | -672.99 Thousand CAD | 28.48% |
| 2015 Q2 | -940.96 Thousand CAD | -26.29% |
| 2014 Q1 | -586.95 Thousand CAD | -44.78% |
| 2014 FY | -3.56 Million CAD | -64.8% |
| 2014 Q2 | -1.15 Million CAD | -96.94% |
| 2014 Q3 | -1 Million CAD | 13.28% |
| 2014 Q4 | -823.28 Thousand CAD | 17.87% |
| 2013 Q3 | -731.57 Thousand CAD | -31.86% |
| 2013 Q1 | -473.57 Thousand CAD | 21.29% |
| 2013 FY | -2.16 Million CAD | -0.23% |
| 2013 Q2 | -554.81 Thousand CAD | -17.15% |
| 2013 Q4 | -405.4 Thousand CAD | 44.58% |
| 2012 Q4 | -601.66 Thousand CAD | -9.81% |
| 2012 Q3 | -547.9 Thousand CAD | 48.93% |
| 2012 FY | -2.16 Million CAD | -16.34% |
| 2012 Q1 | -537.28 Thousand CAD | -34.99% |
| 2012 Q2 | -1.07 Million CAD | -99.69% |
| 2011 Q1 | -449.89 Thousand CAD | 56.84% |
| 2011 Q2 | -623.03 Thousand CAD | -38.48% |
| 2011 Q3 | -386.15 Thousand CAD | 38.02% |
| 2011 FY | -1.85 Million CAD | 20.55% |
| 2011 Q4 | -398.02 Thousand CAD | -3.07% |
| 2010 Q1 | -522.56 Thousand CAD | 36.17% |
| 2010 FY | -2.33 Million CAD | 7.49% |
| 2010 Q2 | -525.48 Thousand CAD | -0.56% |
| 2010 Q3 | -246.91 Thousand CAD | 53.01% |
| 2010 Q4 | -1.04 Million CAD | -322.15% |
| 2009 Q4 | -818.68 Thousand CAD | -72.53% |
| 2009 Q2 | -685.63 Thousand CAD | -25.16% |
| 2009 Q1 | -547.81 Thousand CAD | 43.25% |
| 2009 FY | -2.52 Million CAD | 22.22% |
| 2009 Q3 | -474.51 Thousand CAD | 30.79% |
| 2008 FY | -3.24 Million CAD | 9.01% |
| 2008 Q3 | -821.66 Thousand CAD | -49.47% |
| 2008 Q2 | -549.72 Thousand CAD | 26.27% |
| 2008 Q1 | -745.62 Thousand CAD | 23.0% |
| 2008 Q4 | -965.34 Thousand CAD | -17.49% |
| 2007 Q4 | -968.33 Thousand CAD | -67.0% |
| 2007 Q3 | -579.84 Thousand CAD | 40.71% |
| 2007 Q2 | -978 Thousand CAD | 6.35% |
| 2007 Q1 | -1.04 Million CAD | 41.12% |
| 2007 FY | -3.57 Million CAD | 34.83% |
| 2006 Q2 | -696.25 Thousand CAD | 45.13% |
| 2006 Q1 | -1.26 Million CAD | 12.38% |
| 2006 Q3 | -1.73 Million CAD | -149.86% |
| 2006 Q4 | -1.77 Million CAD | -1.96% |
| 2006 FY | -5.47 Million CAD | -23.18% |
| 2005 Q4 | -1.44 Million CAD | -40.55% |
| 2005 Q3 | -1.03 Million CAD | 4.53% |
| 2005 Q2 | -1.07 Million CAD | -21.24% |
| 2005 Q1 | -890.1 Thousand CAD | -34.21% |
| 2005 FY | -4.44 Million CAD | -27.27% |
| 2004 Q2 | -963.65 Thousand CAD | -10.83% |
| 2004 Q3 | -998.14 Thousand CAD | -3.58% |
| 2004 Q1 | -869.45 Thousand CAD | -14.02% |
| 2004 FY | -3.49 Million CAD | 18.93% |
| 2004 Q4 | -663.2 Thousand CAD | 33.56% |
| 2003 Q1 | -938.88 Thousand CAD | 53.4% |
| 2003 FY | -4.31 Million CAD | 15.69% |
| 2003 Q2 | -1.03 Million CAD | -9.84% |
| 2003 Q3 | -1.57 Million CAD | -52.95% |
| 2003 Q4 | -762.56 Thousand CAD | 51.65% |
| 2002 Q3 | -1.02 Million CAD | -19.7% |
| 2002 Q1 | -1.21 Million CAD | 0.0% |
| 2002 Q4 | -2.01 Million CAD | -96.06% |
| 2002 FY | -5.11 Million CAD | 23.7% |
| 2002 Q2 | -858.48 Thousand CAD | 29.15% |
| 2001 FY | -6.7 Million CAD | -102.62% |
| 2000 FY | -3.3 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.35 Million CAD | 42.05% |
| Covalon Technologies Ltd. | -4.48 Million CAD | 56.688% |
| Hemostemix Inc. | -2.33 Million CAD | 16.679% |
| Universal Ibogaine Inc. | 497.15 Thousand CAD | 491.092% |
| Kane Biotech Inc. | -3.35 Million CAD | 42.088% |
| Marvel Biosciences Corp. | -2.31 Million CAD | 16.155% |
| NervGen Pharma Corp. | -17.77 Million CAD | 89.063% |
| XORTX Therapeutics Inc. | -6.38 Million CAD | 69.534% |